Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    15243278 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)
Condition: Osteoporosis, Postmenopausal
Interventions: Drug: MK0217, /Duration of Treatment : 12 Months;   Drug: Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months

Indicates status has not been verified in more than two years